Sugi Predict

Sugi Predict / Compounds / SCHEMBL1493312

SCHEMBL1493312

SCHEMBL1493312

COC(=O)c1cnn(C)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 3/20 0.45
▸ GRN P28799 1/20 0.45
▸ SORT1 Q99523 1/20 0.45
▸ ALDH1A1 P00352 4/20 0.43
▸ LMNA P02545 2/20 0.43
▸ HPGD P15428 1/20 0.43
▸ MAPK1 P28482 2/20 0.43
▸ ATM Q13315 1/20 0.43
▸ L3MBTL1 Q9Y468 2/20 0.42
▸ HTT P42858 1/20 0.42
▸ TSHR P16473 1/20 0.42
▸ RAB9A P51151 1/20 0.42
▸ DHX9 Q08211 1/20 0.41
▸ KDM4E B2RXH2 2/20 0.41
▸ PDK2 Q15119 1/20 0.41
▸ CA12 O43570 2/20 0.41
▸ CA1 P00915 2/20 0.41
▸ CA2 P00918 2/20 0.41
▸ CA7 P43166 2/20 0.41
▸ CA9 Q16790 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13984679 0.83 MKNK1 (0.57) ALDH1A1HPGDPDK2CA12CA1
SCHEMBL6904033 0.82 SMN1; SMN2 (0.41) SMN1; SMN2GRNSORT1ALDH1A1LMNA
SCHEMBL10564432 0.80 ALDH1A1 (0.43) ALDH1A1LMNAMAPK1ATML3MBTL1
SCHEMBL24786159 0.79 SMN1; SMN2 (0.49) SMN1; SMN2GRNSORT1ALDH1A1LMNA
SCHEMBL30159225 0.79 GPR119 (0.43) SMN1; SMN2GRNSORT1ALDH1A1LMNA
SCHEMBL358469 0.79 CYP2C9 (0.47) SMN1; SMN2GRNSORT1ALDH1A1LMNA
SCHEMBL28966404 0.79 SMN1; SMN2 (0.39) SMN1; SMN2GRNSORT1ALDH1A1LMNA
SCHEMBL476195 0.79 PDK2 (0.49) ALDH1A1LMNAL3MBTL1KDM4EPDK2
SCHEMBL28147463 0.79 VNN1 (0.49) SMN1; SMN2GRNSORT1ALDH1A1LMNA
SCHEMBL11246947 0.78 ALDH1A1 (0.42) ALDH1A1LMNAMAPK1ATML3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4729514-A1 BICYCLIC DERIVATIVE PARP INHIBITOR AND USE THEREOF Haisco Pharmaceutical Group Co., Ltd. (CN) 2026-04-22 — — EP disclosed
US-12435092-B2 Substituted imidazo[1,2-A]quinazolines as inhibitors of PARG 858 THERAPEUTICS, INC. (US) 2025-10-07 — — US disclosed
EP-4526304-A1 INHIBITORS OF PARG 858 Therapeutics, Inc. (US) 2025-03-26 — — EP disclosed
CN-116348109-B Piperazine derivative, and preparation method and application thereof 浙江海正药业股份有限公司 2025-01-21 — — CN disclosed
WO-2024255782-A1 BICYCLIC DERIVATIVE PARP INHIBITOR AND USE THEREOF 西藏海思科制药有限公司 2024-12-19 — — WO disclosed
US-20240352018-A1 SUBSTITUTED IMIDAZO[1,2-a]QUINAZOLINES AND IMIDAZO[1,2-a]PYRIDO[4,3-e]PYRIMIDINES AS INHIBITORS OF PARG 858 THERAPEUTICS, INC. 2024-10-24 — — US disclosed
WO-2024194607-A1 PYRIMIDO[4,5-B][1,5]NAPHTHYRIDINE-4,5(3H,10H)-DIONE DERIVATIVES FOR THE TREATMENT OF DISEASES ASSOCIATED WITH PTC MUTATIONS, SUCH AS E.G. CANCER Tay Therapeutics Limited (GB) 2024-09-26 — — WO disclosed
US-11939335-B2 Substituted imidazo[1,2-a]quinazolines and imidazo [1,2-a]pyrido[4,3-e]pyrimidines as inhibitors of PARG 858 THERAPEUTICS, INC. (US) 2024-03-26 — — US disclosed
EP-4334307-A1 CDK2 DEGRADERS AND USES THEREOF Kymera Therapeutics, Inc. (US) 2024-03-13 — — EP disclosed
WO-2023224998-A1 INHIBITORS OF PARG 858 THERAPEUTICS, INC. (US) 2023-11-23 — — WO disclosed
US-20150284380-A1 NOVEL HETEROCYCLIC COMPOUNDS AS PEST CONTROL AGENTS BAYER CROPSCIENCE AG (DE) 2015-10-08 — — US disclosed
CN-103319462-B Preparation method of halosulfuron methyl JIANGSU AGROCHEM LAB CO LTD 2015-07-08 — — CN disclosed
CN-103319462-A Preparation method of halosulfuron methyl JIANGSU AGROCHEM LAB CO LTD 2013-09-25 — — CN disclosed
EP-2470539-A1 RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF Array Biopharma, Inc. (US) 2012-07-04 — — EP disclosed
US-20120157451-A1 RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF GENENTECH, INC (US) 2012-06-21 — — US disclosed
WO-2011025951-A1 RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF ARRAY BIOPHARMA INC. (US) 2011-03-03 — — WO disclosed
US-7175976-B2 Silver halide photographic light-sensitive material FUJI PHOTO FILM CO., LTD. (JP) 2007-02-13 — — US disclosed
EP-1710234-A1 MALONONITRILE COMPOUND AND USE THEREOF Sumitomo Chemical Company, Limited (JP) 2006-10-11 — — EP disclosed
EP-1329160-A2 4-ACYLAMINOPYRAZOLE DERIVATIVES Sankyo Company, Limited (JP) 2003-07-23 — — EP disclosed
US-6153752-A Process for preparing heterocycles CREANOVA, INC. (US) 2000-11-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12435092-B2 Substituted imidazo[1,2-A]quinazolines as inhibitors of PARG PARG, PLG, PTGIS SMN1; SMN2 3675/4885GRN 635/4885SORT1 4706/4885
US-20120157451-A1 RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF BRAF, RAF1, ARAF SMN1; SMN2 1935/4885GRN 2828/4885SORT1 3781/4885
US-20150284380-A1 NOVEL HETEROCYCLIC COMPOUNDS AS PEST CONTROL AGENTS DDT, KEAP1, NISCH SMN1; SMN2 2786/4885GRN 2063/4885SORT1 4674/4885
US-20240352018-A1 SUBSTITUTED IMIDAZO[1,2-a]QUINAZOLINES AND IMIDAZO[1,2-a]PYRIDO[4,3-e]PYRIMIDINES AS INHIBITORS OF PARG PARG, PLG, PARN SMN1; SMN2 2827/4885GRN 810/4885SORT1 4731/4885
US-11939335-B2 Substituted imidazo[1,2-a]quinazolines and imidazo [1,2-a]pyrido[4,3-e]pyrimidines as inhibitors of PARG PARG, PTGIS, PLG SMN1; SMN2 3254/4885GRN 927/4885SORT1 4821/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.